

SCIENTIFIC PROGRAM*

(*Subject to change)

Wednesday, 6 March, 2024

| | | | | | | |
|-------------|---|---|---|--|---|---|
| 13:00-14:15 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | |
| 14:30-14:40 | Break to Change Halls | | | | | |
| 14:40-16:10 | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | #dedoc° Symposium WHAT WE WISH YOU KNEW – AND WHY (14:40 – 16:00) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) |
| 16:10-16:20 | Break to Change Halls | | | | | |
| 16:20-17:50 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | |
| 18:00-18:40 | OPENING SESSION | | | | | |
| | Moshe Phillips - Opening Remarks Melanie Davies – A new era in the management of T2DM and obesity – Scanning what's on the horizon | | | | | |
| 18:40-19:00 | OPENING EVENT | | | | | |
| 19:00-20:00 | NETWORKING RECEPTION (in the Exhibition Area) | | | | | |

Thursday, 7 March, 2024

| | | | | | | | | |
|-------------|--|--|--|---|---|---|--|----------------|
| 08:00-09:00 | HOT FROM THE OVEN | | | | | | | |
| | <p>Jennifer Sherr - A more comprehensive metabolic picture: Pairing continuous glucose and ketone sensors to detect early DKA</p> <p>Julio Rosenstock - Update on the SURPASS-6 trial testing Tirzepatide vs. Insulin Lispro to advance Basal Insulin Therapy: Emerging horizons beyond Basal-Bolus Insulin Therapy in T2DM</p> <p>Michael Bergman - ONLINE FIRST RELEASE on: IDF position statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycemia and type 2 diabetes</p> | | | | | | | |
| 09:00-10:00 | PLENARY 1 - TOWARD THE FUTURE | | | | | | | |
| | <p>Moshe Phillip - From dream to reality - The Automated Insulin Delivery (AID) system</p> <p>Boris Kovatchev - Neural-Net artificial pancreas</p> <p>Camillo Ricordi - From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions</p> | | | | | | | |
| 10:00-10:30 | COFFEE BREAK, EXHIBITION & E-POSTERS | | | | | | | |
| 10:30-12:00 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | | | |
| 12:00-13:00 | LUNCH BREAK, EXHIBITION & E-POSTERS | | | | | | | |
| 13:00-14:30 | PARALLEL SESSION 1 AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES | PARALLEL SESSION 2 CGM DIABETES QUALITY MEASURES | PARALLEL SESSION 3 HYPOGLYCEMIA - ANY PROGRESS? | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | JDRF - PARALLEL SESSION 4 INTERNATIONAL CONSENSUS MONITORING GUIDANCE FOR PRESYMPTOMATIC (EARLY STAGE) TYPE 1 DIABETES | PARALLEL SESSION 5 INTERVENTION AND PREVENTION OF TYPE 1 DIABETES | PARALLEL SESSION 6 COPING WITH OBESITY | ORALS 1 |
| | <p>Anders Carlson – Use of AID in patients with type 2 diabetes</p> <p>Roman Hovorka - Fully closed-loop in type 1 and type 2 diabetes</p> <p>Bruce Bode - Management of glucose in the hospital with AID systems</p> <p>May Ng - Bringing technology to diabetes care - From evidence to policy</p> | <p>Irl Hirsch - What has the GMI taught us about A1C?</p> <p>Elisabeth Selvin - Should A1C still be a diagnostic criterion for diabetes in 2024?</p> <p>Gregg Simonson – CGM (GMI/TIR) as diabetes quality metrics</p> <p>Guido Freckmann - International standard for evaluation of CGM systems: Approach of the IFCC</p> | <p>Stephanie Amiel – CGM detection of hypoglycemia in diabetes management</p> <p>Simon Heller - Should the classification of hypoglycemia be updated?</p> <p>Pratik Choudhary - Implication of HypoMETRICS for reporting hypoglycemia in clinical trials</p> <p>Bastiaan de Galan - Impaired awareness of hypoglycemia</p> | | <p>Moshe Phillip - The rationale for consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Linda DiMeglio - Summary of the consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Kirstine Bell - Implications for research and clinical care</p> <p>Emanuele Bosi - Population screening for type 1 diabetes is now a reality: An update from Italy</p> | <p>Teresa Rodriguez-Calvo - Role of viruses in pathogenesis of type 1 diabetes</p> <p>Rohit Kulkarni - Targeting mRNA modifications to counter type 1 diabetes</p> <p>Roberto Mallone - Benign autoimmunity & progression to type 1 diabetes</p> <p>Desmond Schatz – Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors</p> | <p>Emma Wilmot – Technology-supported behavior intervention in type 2 diabetes</p> <p>Max Nieuwdorp - A balanced view on microbiome in obesity</p> <p>Luca Busetto – Will new pharmacological treatment for obesity and early diabetes replace bariatric surgery?</p> <p>Primož Kotnik Managing severe obesity in pediatric population</p> | |

| | | | | | | | | |
|-------------|--|--|----------------|--|--|---|--|----------------|
| 14:30-14:40 | Break to Change Halls | | | | | | | |
| 14:40-16:10 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | | | |
| 16:10-16:40 | COFFEE BREAK, EXHIBITION & E-POSTERS | | | | | | | |
| 16:40-18:10 | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL SESSION 7 STANDARDIZATION OF PROS | ORALS 2 | PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY | PARALLEL SESSION 9 THE EFFECT OF DIABETES ON BRAIN HEALTH | PARALLEL SESSION 10 HYBRID CLOSED-LOOP FOR TYPE 2 DIABETES - HURDLES AND BENEFITS | PARALLEL SESSION 11 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY | ORALS 3 |
| | <p><u>Oliver Schnell</u> - What PROs mean in routine clinical care</p> <p><u>Katharine Barnard-Kelly</u> - Consensus statement summary, navigating the maze of PROs</p> <p><u>Mary Murphy</u> - What inclusion of quality PRO assessment in clinical trials means to people with diabetes</p> <p><u>Alon Liberman</u> - Real world data from type 1 diabetes clinics</p> | <p><u>Oliver Schnell</u> - What PROs mean in routine clinical care</p> <p><u>Katharine Barnard-Kelly</u> - Consensus statement summary, navigating the maze of PROs</p> <p><u>Mary Murphy</u> - What inclusion of quality PRO assessment in clinical trials means to people with diabetes</p> <p><u>Alon Liberman</u> - Real world data from type 1 diabetes clinics</p> | | <p><u>Celeste Durnwald</u> – Can CGM replace the oral glucose tolerance test for diagnosis of gestational diabetes?</p> <p><u>Eleanor Scott</u> - CGM glucose trajectories associated with large and small for gestational age birthweight</p> <p><u>Helen Murphy</u> – Should everyone with type 1 diabetes be offered closed-loop during pregnancy?</p> <p><u>Yariv Yogev</u> - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?</p> | <p><u>Mark Strachan</u> - Update on diabetes-associated cognitive dysfunction</p> <p><u>Tali Cukierman-Yaffe</u> - Diagnosis & monitoring of brain health in people with diabetes</p> <p><u>Hertzel Gerstein</u> - Brain aging in people with diabetes - Possible intervention</p> <p><u>David Tanne</u> - Novel approaches and the role of technology in treating brain aging in people with diabetes</p> | <p><u>Yves Reznik</u> - Closed-loop as home care for type 2 diabetes: The Close study</p> <p><u>Charlotte Boughton</u> - Cumulated experience with CamAPS in type 2 diabetes</p> <p><u>Gregory Forlenza</u> - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes</p> <p><u>Anne Peters</u> - Pod use for closed-loop in type 2 diabetes</p> | <p><u>Lori Laffel</u> - Interventions to reduce health disparities in diabetes device use</p> <p><u>V Mohan</u> – Innovating to use existing technologies under resourced settings</p> <p><u>Partha Kar</u> - Widening clinical use of diabetes tech in the UK</p> <p><u>Stuart Weinzimer</u> - Strategies to facilitate technology use in disadvantaged youth with diabetes</p> <p><u>Ananta Addala</u> - Solutions for equity: A call to action</p> | |

Friday, 8 March, 2024

| | | | | | | | | |
|-------------|--|---|---|---|---|---|---|----------------|
| 08:30-09:20 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | | | |
| 09:20-09:30 | Break to change halls | | | | | | | |
| 09:30-10:30 | EUDF - PARALLEL SESSION 12 AI DRIVEN CLINICAL DECISION SUPPORT SYSTEMS - POTENTIAL, CONCERNS AND WHAT TO EXPECT? | PARALLEL SESSION 13 DUAL AND TRIPLE AGONISTS IN DIABETES AND OBESITY | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL SESSION 14 SKIN PROBLEMS IN DIABETES | PARALLEL SESSION 15 WEEKLY INSULINS | PARALLEL SESSION 16 PRACTICAL USE OF CGM | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | ORALS 4 |
| | <p><u>Stefano Del Prato</u> – Welcome and introduction</p> <p><u>Lutz Heinemann</u> - AI for diabetes management and state-of-the art today</p> <p><u>Mia Barjamagic</u> - Potential & concerns linked to the use of AI from the PwD perspective</p> <p><u>Tadej Battelino</u> - Implementing AI: Roadmap and guidelines</p> <p>Q&A and Discussion</p> | <p><u>Viral Shah</u> – GLP-1RA and SGLT in type 1 diabetes</p> <p><u>Michael Camilleri</u> - Pharmacological intervention with dual and triple agonists in obesity: Clinical efficacy and effects on stomach emptying</p> <p><u>Andrej Janež</u> – Incretins and taste</p> | | <p><u>Anna Korsgaard Berg</u> - Skin problems caused by diabetes devices</p> <p><u>Julia Mader</u> - Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/traing and awareness of HCP and PwD</p> <p><u>Deirdre Fitzgerald Huges</u> - Shining a light on diabetic foot infections, development of novel photodynamic materials</p> | <p><u>Julio Rosenstock</u> – Update on weekly insulin Icodec: The way of the future</p> <p><u>Juan Frias</u> – Update on weekly insulin Efsitora</p> <p><u>Chantal Mathieu</u> – CGM derived data on weekly insulins</p> | <p><u>Cari Berget</u> - Technology pearls for professionals</p> <p><u>Steven Edelman</u> – Top 10 tips to help people with diabetes (PwD) stay in range</p> <p><u>Steven Edelman and Jeremy Pettus</u> – Rapid fire interpretations of CGM downloads</p> | | |
| 10:30-11:00 | COFFEE BREAK, EXHIBITION & E-POSTERS | | | | | | | |
| 11:00-12:30 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | | | |

| | |
|-------------|--|
| 12:30-13:30 | LUNCH BREAK, EXHIBITION & E-POSTERS |
| 13:30-15:00 | PLENARY 2 ATTD YEARBOOK SESSION |
| | <p><u>Klemen Dovc</u> - Continuous and intermittent glucose monitoring</p> <p><u>Rayhan A. Lal</u> - Insulin delivery hardware: pumps and pens</p> <p><u>Lutz Heinemann</u> - New insulins, biosimilars and insulin therapy</p> <p><u>Mark Clements</u> - Closed-loop, artificial intelligence-based decision support systems and data science</p> <p><u>Mark Clements</u> - Using digital health technology to prevent and treat diabetes</p> <p><u>Jennifer M. Yamamoto</u> - Technology and pregnancy</p> <p><u>David M. Maahs</u> - Diabetes technology and therapy in the pediatric age group</p> <p><u>Dessi P. Zaharieva</u> - Advances in exercise and nutrition as therapy in diabetes</p> <p><u>Thomas W. Martens</u> - Primary care and diabetes technologies and treatments</p> <p><u>Medha Munshi</u> - Use of technologies at the advanced age</p> <p><u>Ananta Addala</u> - Diabetes technology in the “real world”: Expanding access and addressing disparities</p> <p><u>Alon Liberman</u> - Diabetes technology and the human factor</p> <p><u>Desmond Schatz</u> - Immune interventions and restorative therapies in type 1 diabetes</p> <p><u>Viral N. Shah</u> - Obesity, NAFLD/NASH and diabetes</p> <p><u>Satish K. Garg</u> - Virtual clinics for diabetes care</p> <p><u>Satish K. Garg</u> - New medications for the treatment of diabetes</p> |
| 15:00-15:15 | Break |
| 15:15-16:45 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) |
| 16:45-17:15 | COFFEE BREAK, EXHIBITION & E-POSTERS |

| | | | | | | | | |
|-------------|--|---|---|---|--|---|---|--------------------|
| 17:15-18:45 | PARALLEL SESSION 17 OBESITY IN TYPE 1 DIABETES | PARALLEL SESSION 18 AUTOMATED INSULIN DELIVERY IN CHILDREN | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES (17:15-18:05) | PARALLEL SESSION 20 CGM GUIDED PRECISION DIABETES MANAGEMENT | PARALLEL SESSION 21 INTEROPERABILITY O DIABETES TECHNOLOGY | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | ORALS 5 |
| | <p><u>Satish Garg</u> - Management options for treating obesity in type 1 diabetes patients</p> <p><u>Jeremy Pettus</u> - Insulin resistance in type 1 diabetes: An underappreciated problem</p> <p><u>Kirsten Nørgaard</u> - Effects of GLP1 in type 1 diabetes</p> <p><u>Victor Gerdes</u> - Bariatric surgery in diabetes</p> | <p><u>Revital Nimri</u> - Maximizing glycemic control with automated insulin delivery in young children</p> <p><u>Thomas Danne</u> – Worldwide progress achieving treatment targets in children with type 1 diabetes</p> <p><u>Ivana Rabbone</u> - Technology in the changing management of diabetes in children</p> <p><u>Nataša Bratina</u> - Data on diabetes treatment in children below the age of six</p> | | <p><u>Mark Clements</u> – Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior</p> <p><u>John Leth</u> - The potential of open-source software in diabetes research</p> <p><u>Heiko Peuscher</u> - A survey on existing open-source projects in diabetes simulation</p> | <p><u>Tara Ettestad</u> - CGM Guided Nutrition</p> <p><u>Michael Riddell</u> - CGM guided exercise</p> <p><u>Thomas Martens</u> – CGM guided insulin management</p> <p><u>Darja Šmigoc Schweiger</u> - Guided management of diabetes in female</p> | <p><u>David Klonoff</u> – Interoperability of diabetes technology Academic view</p> <p><u>Alexander Olbrechts</u> - Interoperability of diabetes technology - A company's view</p> <p><u>Johan Jendle</u> - Interoperability of diabetes technology - Regulatory hurdle</p> <p><u>Tim Street</u> – Interoperability of diabetes technology - Patient's view</p> | | |
| | | | | Short Break | | | | |
| | | | | PARALLEL SESSION 22 TECH IT OUT OF THE BOX: PAPERS, POLICY, PATIENTS (18:15-18:45) | | | | |
| | | | | <p><u>Partha Kar</u> Introduction</p> <p><u>Partha Kar</u> - Challenges of getting technology into policy</p> <p><u>Eleanor Scott</u> - CGM in Pregnancy</p> <p><u>Jazz Sethi</u> - D-Coding tech research into reality</p> | | | | |
| 18:45-18:55 | | | | | | | | |
| 18:55-20:25 | IGNITE START-UP NETWORKING EVENT (not included in the main event CME/CPD credit) | | | | ATTD PARTNER EVENT (not included in the main event CME/CPD credit) (19:15 – 21:30) | | | |

Saturday, 9 March, 2024

| | | | | | | | |
|-------------|--|---|----------------|---|--|--|--------------------|
| 08:30-09:20 | PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | | | | |
| 09:20-09:30 | Break to Change Halls | | | | | | |
| 09:30-11:00 | PARALLEL SESSION 23 DECISION SUPPORT AND AUTOMATED INSULIN DELIVERY FOR THE MANAGEMENT OF TYPE 2 DIABETES | PARALLEL SESSION 24 CHALLENGES IN METABOLIC CONTROL | ORALS 6 | PARALLEL SESSION 25 CGM CLINICAL WORKFLOW | PARALLEL SESSION 26 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES | PARALLEL SESSION 27 NUTRITION AND FOOD TECHNOLOGIES | ORALS 7 |
| | <p><u>Chiara Fabris</u> - Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D</p> <p><u>Lia Bally</u> - Virtual clinic for insulin therapy in type 2 diabetes</p> <p><u>Morten Hasselstrøm Jensen</u> - Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project</p> | <p><u>Richard Bergenstal</u> - We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia</p> <p><u>Elisabeth Selvin</u> - Diabetes and cognitive decline and dementia</p> <p><u>Francesco Giorgino</u> - Addressing glucose patterns in type 2 diabetes: Opportunities and challenges</p> <p><u>Nebojsa Lalic</u> - Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease</p> | | <p><u>David Maahs</u> - Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study</p> <p><u>Amy Criego</u> – CGM Success: Device start and ongoing data management to improve patient care</p> <p><u>Nana Jones</u> - Integration of CGM data into the EMR – Challenges and successes</p> <p><u>Xavier Cos</u> - Use of CGM by the primary care providers</p> | <p><u>Emanuele Bosi</u> – Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool?</p> <p><u>Laura Jacobsen</u> – Immune therapy – Predicting responders/non-responders</p> <p><u>Jennifer Sherr</u> – Teplizumab therapy in the real world</p> <p><u>Raffaella Buzzetti</u> – Antibody positivity in adult population</p> | <p><u>Michal Gillon-Keren</u> - Facilitate carb counting for people with diabetes</p> <p><u>Laya Ekhlaspour</u> - Beyond carbohydrate counting: Optimizing mealtime insulin dosing</p> <p><u>Peter Jacobs</u> - Unannounced meal detection algorithms: Can we eliminate manual meal boluses?</p> <p><u>Daria Igudesman</u> - Diet, microbiome, obesity and type 1 diabetes</p> | |
| 11:00-11:30 | COFFEE BREAK, EXHIBITION & E-POSTERS | | | | | | |

| | | | | | | | | |
|-------------|---|--|----------------|---|--|--|--|----------------|
| 11:30-13:00 | PARALLEL SESSION 28 TO CGM OR NOT TO CGM? | PARALLEL SESSION 29 SPORT IN DIABETES | ORALS 8 | PARALLEL SESSION 30 GENDER DIFFERENCES IN DIABETES MANAGEMENT AND GLUCOSE CONTROL | JDRF - PARALLEL SESSION 31 CELL REPLACEMENT THERAPY | PARALLEL 32 ADVANCES IN TREATING DIABETES | PARALLEL SESSION 33 TECHFAIR WINNERS' PRESENTATIONS | ORALS 9 |
| | <p><u>Tadej Battelino</u> - CGM derived criteria for stage 2 type 1 diabetes</p> <p><u>Leon Farhy</u> – Diagnostic CGM</p> <p><u>Anders Carlson</u> - The use of CGM in prediabetes and obesity</p> <p><u>Dario Rahelic</u> - Use of CGM in nutrition management in type 2 diabetes</p> | <p><u>Klemen Dovc</u> - Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability</p> <p><u>Michael Riddell</u> - Lessons learned from the ongoing type 1 diabetes exercise research initiative</p> <p><u>Kirsten Nørgaard</u> - Low-dose glucagon to prevent hypoglycemia during exercise</p> <p><u>Dessi Zaharieva</u> - Translation of exercise guidelines into practical applications for type 1 diabetes</p> | | <p><u>Eda Cengiz</u> - Update on diabetes Female Technology (femtech)</p> <p><u>Chiara Fabris</u> - What do women want (and need)? Results from the large-scale IMAGINE survey</p> <p><u>Jane Yardley</u> - Challenges of exercise in women with type 1 diabetes</p> <p><u>Brynn Marks</u> - Insulin delivery is automated, but the education is not: Mothering diabetes technology users</p> | <p><u>Ester Latres</u> - Introduction</p> <p><u>Peter Senior</u> - 20-year outcomes of islet cell transplantation - The benchmark for stem cells?</p> <p><u>Qizhi Tang</u> - Engineering beta cells to enable immunosuppression-free replacement therapy for type 1 diabetes</p> <p><u>José Oberholzer</u> - Islet cell replacement therapy for type 1 diabetes</p> <p>Round Table</p> | <p><u>Peter Adolfsson</u> - Current use of connected pens</p> <p><u>Fernando Gómez Peralta</u> - Connected insulin pens and caps: An expert's recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN)</p> <p><u>Christophe de Block</u> – Ketone continuous measurement – Is it needed?</p> <p><u>Andrea Facchinetti</u> - Digital twin technologies for treating diabetes</p> <p><u>Neal Kaufman</u> - The importance and impact of family caregivers on a variety of outcomes for people with diabetes</p> | | |
| 13:00-13:45 | LUNCH BREAK, EXHIBITION & E-POSTERS | | | | | | | |

| | | | | | | | |
|-------------|--|---|-----------------|---|---|---|-----------------|
| 13:45-15:15 | PARALLEL SESSION 34 OBESITY AND TYPE 2 DIABETES | PARALLEL SESSION 35 DIABETES IN ITALY | ORALS 10 | ISPAD/ATTD - PARALLEL SESSION 36 DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES | PARALLEL SESSION 37 DTECH SYMPOSIUM - DIABETES IN INDIA | PARALLEL SESSION 38 SARCOPENIA, FRAILTY AND DIABETES | ORALS 11 |
| | <p><u>Antonio Ceriello</u> - Weight and glycemic variability: Bad companions for CVD development in diabetes</p> <p><u>Kamlesh Khunti</u> - Early intervention for type 2 diabetes in primary care</p> <p><u>Barbara McGowan</u> - Medical therapies for treatment of obesity</p> <p><u>Jernej Kovac</u> - Genetic background of obesity</p> | <p><u>Marco Marigliano</u> - Relationships between insulin delivery system, CGM satisfaction and glucometrics</p> <p><u>Andrea Scaramuzza</u> - Real-world data in very young AHCL users - Comparison among different systems</p> <p><u>Nicola Minuto</u> - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough</p> <p><u>Sergio di Molfetta</u> - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated</p> | | <p><u>Renza Scibilia</u> – Type 1 diabetes global index and overview of diabetes technology present and future in lower income countries</p> <p><u>Thereza Piloya-Were</u> - Impact of CGM in East Africa, research and translation</p> <p><u>Hamidah Nabakka</u> - Diabetes advocate perspective on diabetes technology in low-income countries</p> | <p><u>Banshi Saboo</u> - Welcome and introduction to Dtech symposium</p> <p><u>Shashank Joshi</u> - Artificial intelligence in diabetes care</p> <p><u>Jothydev Kesavadev</u> - 25 years of telemedicine vs. conventional care in diabetes: Assessing vascular complications and quality of life</p> <p><u>Manoj Chawla</u> - Optimizing real time CGM in self-pay markets</p> <p><u>Amit Gupta</u> - Challenges and opportunities in digital diabetes care in India</p> <p><u>Mithun Bhartia</u> - Diabetes and sex life – The role of technology to improve quality of life</p> <p><u>Rakesh Parikh</u>: Artificial Intelligence in the management of diabetes</p> | <p><u>Alan Sinclair</u> - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance</p> <p><u>Leocadio Rodríguez Mañas</u> - Current treatment options for sarcopenia in the context of frail older people with diabetes</p> <p><u>Tali Cukierman-Yaffe</u> - How to measure and monitor sarcopenia and frailty</p> | |

| | |
|-------------|---|
| 15:15-15:25 | Break to Change Halls |
| 15:25-16:25 | PLENARY 3 CURE OF DIABETES |
| | <u>Michael Haller</u> - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications <u>Jay Skyler</u> - Stem cell approaches to type 1 diabetes <u>Michael Rickels</u> - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes |
| 16:25-17:00 | CLOSING REMARKS |
| 17:00 | FAREWELL REFRESHMENTS |